Health Care & Life Sciences » Biotechnology | Clovis Oncology Inc.

Clovis Oncology Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
13,625.00
-
78.00
55,511.00
95,388
Cost of Goods Sold (COGS) incl. D&A
250.00
3,853.00
761.00
1,211.00
11,737.00
22,074
Gross Income
250.00
9,772.00
761.00
1,133.00
43,774.00
73,314
SG&A Expense
80,662.00
158,718.00
299,014.00
290,719.00
281,405.00
407,128
EBIT
80,912.00
148,946.00
299,775.00
291,852.00
237,631.00
333,814
Unusual Expense
2,855.00
9,513.00
76,946.00
80,881.00
105,477.00
27,975
Non Operating Income/Expense
713.00
3,340.00
3,156.00
53.00
3,561.00
7,571
Interest Expense
-
2,604.00
8,372.00
8,491.00
10,428.00
13,183
Pretax Income
84,480.00
157,723.00
381,937.00
381,171.00
349,975.00
367,401
Income Tax
52.00
2,308.00
29,076.00
32,034.00
3,578.00
608
Consolidated Net Income
84,532.00
160,031.00
352,861.00
349,137.00
346,397.00
368,009
Net Income
84,532.00
160,031.00
352,861.00
349,137.00
346,397.00
368,009
Net Income After Extraordinaries
84,532.00
160,031.00
352,861.00
349,137.00
346,397.00
368,009
Net Income Available to Common
84,532.00
160,031.00
352,861.00
349,137.00
346,397.00
368,009
EPS (Basic)
2.95
4.72
9.79
9.07
7.36
7.07
Basic Shares Outstanding
28,672.00
33,889.00
36,026.00
38,478.00
47,047.00
52,066
EPS (Diluted)
2.95
4.72
9.79
9.07
7.36
7.07
Diluted Shares Outstanding
28,672.00
33,889.00
36,026.00
38,478.00
47,047.00
52,066
EBITDA
80,662.00
145,093.00
299,014.00
290,711.00
235,127.00
329,213

About Clovis Oncology

View Profile
Address
5500 Flatiron Parkway
Boulder Colorado 80301
United States
Employees -
Website http://www.clovisoncology.com
Updated 07/08/2019
Clovis Oncology, Inc. engages in the acquisition, development, and commercialization of anti-cancer agents. Its marketed product, Rubraca, seeks to treat patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies. It also has product candidates, namely Rociletinib and Lucitanib.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.